80 million Americans have sleep apnea

50 million don't know it

Apnova is building a better path to diagnosis

The Problem

A widespread condition, widely missed

Sleep apnea is one of the most common chronic conditions in the United States — and one of the most underdiagnosed. The gap between prevalence and diagnosis has significant clinical and economic consequences.

0
Estimated U.S. adults with sleep apnea
[1] Sönmez et al., Sleep, 2025
0
Of moderate-to-severe cases remain undiagnosed
[2] AASM estimates
0
Annual U.S. economic cost of undiagnosed sleep apnea
[3] AASM / Frost & Sullivan; Alharbi et al., Healthcare, 2025
0
Adults affected globally
[4] Benjafield et al., Lancet Resp. Medicine, 2019
Clinical Impact

A silent epidemic

Untreated sleep apnea is independently associated with increased risk across multiple major disease categories. The consequences extend well beyond sleep.

Cardiovascular Disease
40–80% of patients with cardiovascular disease also have sleep apnea. Associated with hypertension, atrial fibrillation, and heart failure.
Metabolic & Cognitive
Linked to Type 2 diabetes, insulin resistance, and cognitive decline. Sleep apnea compounds risk across multiple chronic conditions.
Mortality Risk
Moderate-to-severe untreated sleep apnea is associated with roughly double the risk of heart attack, stroke, and premature death.

[5] Yeghiazarians et al., AHA Scientific Statement, Circulation, 2021

The Diagnostic Gap

Current testing hasn't kept up

Most home sleep tests still rely on multi-sensor setups — nasal cannulas, chest belts, finger clips — leading to poor patient compliance, failed studies, and repeat testing. The pathway from suspicion to diagnosis to treatment remains fragmented, with patients lost at every handoff.

2,500
AASM-accredited sleep labs
7,500
Board-certified sleep physicians
43,000 : 1
Patient-to-sleep-physician ratio

[6] AASM infrastructure data

At the same time, demand is accelerating. Virtual care is widening the front door for screening. GLP-1 therapies are unmasking previously hidden cases. Payers are focusing on upstream diagnosis to manage downstream costs.

Compliance
Complex setups lead to failed and inconclusive studies
Fragmentation
Diagnosis, interpretation, and treatment are disconnected
Rising demand
Telehealth, awareness, and payer incentives are converging
Our Approach

Device, interpretation, and logistics —
integrated from the start

Apnova is building an end-to-end home sleep testing platform designed to be simpler for patients, more reliable for clinicians, and more efficient for the health system.

1
Order
Physician orders an HSAT through the Apnova portal
→
2
Ship
Device shipped directly to the patient's home
→
3
Sleep
Patient wears the device overnight and ships it back
→
4
Results
Auto-scored, tech-reviewed, physician-interpreted report delivered
Simpler for patients More reliable for clinicians More efficient for the system

Apnova's platform is currently in development. The company is in active engagement with the FDA.

Team

Built by domain experts

Sleep Medicine
Deep expertise in sleep diagnostics and clinical practice
Medtech Engineering
Track record in FDA-cleared diagnostic device development
Regulatory & Clinical
Experience navigating FDA pathways for novel diagnostics
Operations & Growth
Scaled health-tech platforms from zero to national distribution